Industry News

Cigna and Aetna's $37 billion planned acquisition of Humana-- would cut the number of large national insurers from five to three, unacceptably driving up prices and stifling innovation."/>
U.S. sues to block health insurance mergers; cites competitive issues, including in St. Louis [St. Louis Post-Dispatch]
Aetna Inc. and Anthem Inc., with Attorney General Loretta Lynch criticizing the deals as anti-competitive and being pursued "at the expense of consumers across America." Anti-trust lawsuits were filed in District of Columbia federal court against both deals. Anthem has proposed to acquire Bloomfield-based Cigna for $54 billion, and Hartford-based Aetna has sought Humana..."/>
U.S. Suing To Block Aetna-Humana and Anthem-Cigna Mergers [The Hartford Courant]
M and A Navigator: Deal pipeline –22 July
Centene Corporation announced today that the Department of Defense intends to award its wholly-owned subsidiary, Health Net Federal Services, LLC, the TRICARE West Region Contract. Health Net Federal Services currently is the managed care contractor for the TRICARE North Region. The TRICARE West Region contract includes a base period with additional five one-year option periods."/>
Centene's Subsidiary Awarded TRICARE West Region Contract
Spark Therapeutics is planning an expansion that could take it out of the city. While Spark, currently based in University City, has some Philadelphia sites on its radar, it's also considering locations in New Jersey and Delaware, according to brokers at real estate services firm JLL, which is aiding the company in its search. The move to expand comes as Spark-- one of the most..."/>
Expanding drug pioneer Spark mulls move from Philly birthplace [The Philadelphia Inquirer]
VIVUS, Inc. today announced that the United States District Court for the District of New Jersey has issued a claim construction ruling governing patent litigation brought by VIVUS against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis, and Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., collectively referred to as Teva. The lawsuits were filed in response to..."/>
VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
Helix BioPharma Corp., a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. has finalized the Grant Funding Agreement with the Polish National Centre for Research and Development to develop V-DOS47 in breast cancer up to and including a phase I/IIa clinical trial. Funding from the PNCRD will go towards the..."/>
Helix BioPharma Corp. Subsidiary, Helix Polska Sp. z o.o., Finalizes Grant Funding With the Polish National Center for Research and Development
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has named Steven C. Gilman, PhD, as Chief Executive Officer of ContraFect, effective immediately. Gilman has served as Interim Chief Executive Officer since March 21, 2016. He will continue to serve as Chairman of the Board of Directors of the..."/>
ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer
Anthem and Cigna. The suit charges a merge would increase concentration in the industry and harm competition in Tennessee and across the country, ultimately impacting services and prices."/>
Tennessee, Georgia join with feds to block Anthem's purchase of Cigna [Chattanooga Times Free Press, Tenn.]
Humana. LOUISVILLE, Ky.---- On July 21, 2016, after the market close, Humana Inc. was informed by the U.S. Department of Defense that it has been awarded the contract for the TRICARE East Region."/>
Humana Awarded Department of Defense TRICARE East Region Contract
Insmed Incorporated concerning possible violations of federal securities laws between March 18, 2013 and June 8, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 13, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here."/>
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Insmed Incorporated and Reminds Investors With Losses to Contact the Firm
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter 2016 after the close of trading on Thursday, August 4, 2016. The Company’ s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call..."/>
Corindus Vascular Robotics to Report Second Quarter 2016 Financial Results on August 4, 2016
Retrophin, Inc. today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.. A replay of the call will be available from 7:30 p.m. ET, August 4, 2016 to 11:59 p.m. ET, August 11, 2016."/>
Retrophin to Report Second Quarter 2016 Financial Results
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has commenced an underwritten public offering of its common stock and warrants to purchase additional shares of its common stock. All of the securities in the offering are to be sold by ContraFect. Piper Jaffray& Co. is acting as sole..."/>
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
TransEnterix, Inc. announced today that it plans to release second quarter 2016 financial and operating results before the market opens on Friday, August 5, 2016. Todd M. Pope, President and Chief Executive Officer and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 8:30 am Eastern Time the same day. The call will be concurrently webcast."/>
TransEnterix Schedules Second Quarter 2016 Financial and Operating Results Conference Call for August 5, 2016
Gilead Sciences, Inc. today announced that two Phase 3 b switch studies evaluating Odefsey ® for the treatment of HIV-1 infection met their primary objectives. The ongoing studies were designed to explore the efficacy and safety of Odefsey among virologically suppressed adult patients switching from the tenofovir disoproxil fumarate- based regimens Complera ® or Atripla ®. Odefsey combines Gilead’ s emtricitabine and tenofovir alafenamide with..."/>
Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Surgery Partners, Inc., a leading healthcare services company, today announced that the Company will release its second quarter 2016 results after the market close on Tuesday, August 9, 2016, to be followed by a conference call on Wednesday, August 10 at 8:30 a.m... The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can..."/>
Surgery Partners, Inc. Announces Second Quarter 2016 Earnings Release Date and Conference Call Details
Puma Biotechnology, Inc., a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma’ s investigational drug PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer. The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab in women with early stage HER2-positive breast cancer. The ExteNET trial randomized..."/>
Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Heat. Heat intends to grant the underwriters a 45- day option to purchase up to an additional 15 percent of the securities to be sold."/>
Heat Biologics Announces Proposed Public Offering of Common Stock
Emergent BioSolutions Inc. will host a conference call on Thursday, August 4, 2016 at 5:00 pm to discuss the financial results for the second quarter of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.. This conference call can be accessed live by telephone or through Emergent’ s website:. Pre-registering for the live call will expedite access and minimize..."/>
Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials845 Articles
Information Technology737 Articles
Consumer Discretionary685 Articles
Industrials531 Articles
Health Care466 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at